Live donor liver transplantation

Sander Florman, Charles M. Miller – 22 March 2006 – With ever‐increasing demand for liver replacement, supply of organs is the limiting factor and a significant number of patients die while waiting. Live donor liver transplantation has emerged as an important option for many patients, particularly small pediatric patients and those adults that are disadvantaged by the current deceased donor allocation system. Ideally there would be no need to subject perfectly healthy people in the prime of their lives to a potentially life‐threatening operation to procure transplantable organs.

Isolation of hepatocytes from livers from non‐heart‐beating donors for cell transplantation

Robin D. Hughes, Ragai R. Mitry, Anil Dhawan, Sharon C. Lehec, Raffaele Girlanda, Mohamed Rela, Nigel D. Heaton, Paolo Muiesan – 9 March 2006 – One of the limitations to hepatocyte transplantation is the restricted availability of donor liver tissue. The aim of this study was to evaluate livers from non‐heart‐beating donors (NHBDs) as a source of hepatocytes for cell transplantation. A total of 20 livers/segments obtained from NHBD were perfused under good manufacturing practices using a standard collagenase digestion method.

Long‐term incidence, risk factors, and management of biliary complications after adult living donor liver transplantation

Shin Hwang, Sung‐Gyu Lee, Kyu‐Bo Sung, Kwang‐Min Park, Ki‐Hun Kim, Chul‐Soo Ahn, Young‐Joo Lee, Sung‐Koo Lee, Gyu‐Sam Hwang, Deok‐Bog Moon, Tae‐Yong Ha, Dong‐Sik Kim, Jae‐Pil Jung, Gi‐Won Song – 9 March 2006 – A considerable proportion of adult living donor liver transplantation (LDLT) recipients experience biliary complication (BC), but there are few reports regarding BC based on long‐term studies of a large LDLT population.

Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation

Victor I. Machicao, Titte R. Srinivas, Alan W. Hemming, Consuelo Soldevila‐Pico, Roberto J. Firpi, Alan I. Reed, Giuseppi J. Morelli, David R. Nelson, Manal F. Abdelmalek – 9 March 2006 – The implementation of the model for end‐stage liver disease (MELD) score decreased mortality of those awaiting liver transplantation (LT); however, the impact of the MELD allocation system on the risk of chronic renal disease after LT remains unknown. We conducted a non‐concurrent single‐center cohort study of 174 patients undergoing LT at our center.

Fatigue is a major problem after liver transplantation

Rita van den Berg‐Emons, Berbke van Ginneken, Markus Wijffels, Hugo Tilanus, Herold Metselaar, Henk Stam, Geert Kazemier – 9 March 2006 – Fatigue is often experienced after liver transplantation. The aim of this cross‐sectional study was to assess the severity of fatigue in liver transplant recipients. In addition, the nature of fatigue and factors that may be associated with severity of fatigue after liver transplantation were explored. Ninety‐six patients up to 15 years after liver transplantation were included.

Living donor liver transplantation for hepatocellular carcinoma: A single‐center preliminary report

Massimo Malagó, Georgios C. Sotiropoulos, Silvio Nadalin, Camino Valentin‐Gamazo, Andreas Paul, Hauke Lang, Arnold Radtke, Fuat Saner, Ernesto Molmenti, Susanne Beckebaum, Guido Gerken, Andrea Frilling, Christoph E. Broelsch – 9 March 2006 – Liver transplantation (LT) is the treatment of choice for early hepatocellular carcinoma (HCC) in patients with end‐stage liver disease but is limited by the availability of donor organs. Living donor liver transplantation (LDLT) represents an alternative therapeutic option for patients with disease confined to the liver.

Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: Observations in 3 cases

Saiho Ko, Eiji Okano, Hiromichi Kanehiro, Masanori Matsumoto, Hiromichi Ishizashi, Masahito Uemura, Yoshihiro Fujimura, Koichi Tanaka, Yoshiyuki Nakajima – 9 March 2006 – A disintegrin‐like and metalloproteinase with thrombospondin type‐1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves the multimeric von Willebrand factor (VWF). Deficiency of ADAMTS13 increases the unusually large VWF multimers (UL‐VWFM), which leads to platelet clumping and/or thrombus formation, resulting in microcirculatory disturbance.

Subscribe to